Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY2R | P49146 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | SCD | O00767 | 2/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | RORC | P51449 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | GBA1 | P04062 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25933 | 0.87 | POLB (0.58) | NPY2RCYP2C9CYP2C19HTR2BMAPK14 | |
| SCHEMBL16319144 | 0.86 | NPY2R (0.44) | NPY2RCYP2C9CYP2C19HTR2BMAPK14 | |
| SCHEMBL518633 | 0.81 | CYP2C9 (0.53) | CYP2C9CYP2C19HTR2BMAPK14SCD | |
| SCHEMBL2818668 | 0.79 | SPR (0.45) | NPY2RCYP2C9CYP2C19HTR2BMAPK14 | |
| SCHEMBL938275 | 0.78 | POLB (0.48) | NPY2RPOLB | |
| SCHEMBL13261171 | 0.77 | RORC (0.47) | CYP2C9CYP2C19HTR2BMAPK14POLB | |
| SCHEMBL1921758 | 0.77 | CYP2C9 (0.49) | CYP2C9CYP2C19HTR2BMAPK14SCD | |
| SCHEMBL3529473 | 0.76 | POLB (0.55) | POLBP2RX7 | |
| SCHEMBL3951674 | 0.75 | NFKB1 (0.46) | POLBRORCMAPK1 | |
| SCHEMBL2292608 | 0.75 | USP2 (0.52) | MAPK1NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8673917-B2 | 2-heteroaryl-pyrrolo [3,4-C]pyrrole derivatives, and use thereof as SCD inhibitors | SANOFI (FR) | 2014-03-18 | — | — | US | disclosed |
| US-8673917-B2 | 2-heteroaryl-pyrrolo [3,4-C]pyrrole derivatives, and use thereof as SCD inhibitors | SANOFI (FR) | 2014-03-18 | — | — | US | disclosed |
| US-20120028986-A1 | 2-HETEROARYL-PYRROLO [3,4-C]PYRROLE DERIVATIVES, AND USE THEREOF AS SCD INHIBITORS | SANOFI-AVENTIS (FR) | 2012-02-02 | — | — | US | disclosed |
| US-20120028986-A1 | 2-HETEROARYL-PYRROLO [3,4-C]PYRROLE DERIVATIVES, AND USE THEREOF AS SCD INHIBITORS | SANOFI-AVENTIS (FR) | 2012-02-02 | — | — | US | disclosed |
| WO-2010028761-A1 | 2-HETEROARYL-PYRROLO [3, 4-C]PYRROLE DERIVATIVES AND THE USE THEREOF AS SCD INHIBITORS | SANOFI-AVENTIS (FR) | 2010-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028986-A1 | 2-HETEROARYL-PYRROLO [3,4-C]PYRROLE DERIVATIVES, AND USE THEREOF AS SCD INHIBITORS | SCD, SCD5, PC | NPY2R 507/4885CYP2C9 692/4885CYP2C19 566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.